Pilot study of adjuvant frameless stereotactic radiotherapy to the surgical cavity in patients with brain metastases.
(coautores junto a Canales S, Arnalte R, Vargas E, Toscas S). ESTRO Anniversary Meeting. Londres (Inglaterra). Junio 2011.Prostate cancer radiotherapy outcome: alpha/beta = 1.4 (0.9–2.2) Gy from 5969 patients, and no dose-response for high-dose-rate brachytherapy in 1207 patients.
Ponente. 14th International Congress of Radiation Research. Varsovia (Polonia). Septiembre 2011.SBRT for prostate cancer: approaches and treatment outcome.
Ponente. SBRT Symposium 2011. Amsterdam (Holanda). Enero 2011.RT stéréotaxique du cancer de la prostate: hypofractionnement et irradiation ciblée de la région tumorale dominante pour une majoration de dose optimale. Novalis Launch Symposium. Reims (Francia). Marzo 2011. RT stéréotaxique du cancer de la prostate: h
Ponente. Novalis Launch Symposium. Reims (Francia). Marzo 2011.Evaluation of hypofractionated prostate radiosurgery.
Ponente. 3rd European Novalis Radiosurgery Symposium. Freiburg (Alemania). Noviembre 2011.Stereotactic body radiotherapy : prostate cancer.
Ponente. 7th Modular Course on Stereotactic Radiotherapy and Radiosurgery. Bad Saarow (Alemania). Octubre 2011.Radiation oncology: biology and physics; clinical applications.
Instituto Científico Europeo. Archamps (Francia). Marzo 2011.Introduction to cellular radiation biology/Clinical applications of 3D radiotherapy.
Instituto Científico Europeo. Archamps (Francia). Noviembre 2011.
Extreme hypofractionated intensity modulated radiotherapy in stereotactic conditions for cT1c - cT3a prostate cancer with a low risk of nodal metastases (? 20%, Roach index): a Novalis Circle Phase I-II prospective randomized Trial.
Investigador principal en Centro Medico Teknon: Raymond Miralbell MD y Servei de Radio-Oncologia de Institut Oncològic Teknon. Co-investigador: Dra. Sandra Jorcano. Promotor: Raymond Miralbell MD del Hôspitaux Universitaires de Genève y Servei de Radio-oncologia de Institut Oncològic Teknon.
Extreme hypofractionated intensity modulated radiotherapy in stereotactic conditions for cT1c-cT3a préstate cancer with a low risk for nodal metastases (<20%, Roach index): a Novalis Circle Ohase II prospective randomized trial.
Investigador principal: Dr. Raimon Miralbell, 2011. Writing Committee Member: Dr. Salvador Villà F.Área principal de investigación clínica sobre el cáncer de próstata: Imaging for radiotherapy treatment planning; Treatment precision optimization through image guided radiotherapy; Tracing of the biochemical relapse after curative surgery or radiotherapy
Investigador principal: Dr. Raimon Miralbell.Extreme hypofractionated intensity modulated radiotherapy in stereotactic conditions for cT1c - cT3a prostate cancer with a low risk of nodal metastases (? 20%, Roach index): a Novalis Circle Phase I-II prospective randomized Trial.
Estudio clínico prospectivo, abierto de 24 meses: Complemento de dosis “boost” sobre el lecho tumoral con radioterapia mediante un arco dinámico conformado (DCAT-sistema Novalis), en pacientesdiagnosticadas de cáncer de mama en estadio inicial tras cirugí
Investigador principal en Centro Médico Teknon: Dr. Raimond Miralbell y Co-Investigador: Dr. José Ignacio Toscas V.Fractionated image-guided stereotactic radiotherapy boost in a stage IIB endometrial cancer using the Novalis system, chapter 21E. En: Image-guided Radiation Therapy.
2011. Eds.: A.J. Mundt and J. Roeske. People’s Medical Publishing House –USA Shelton, Connecticut.Stereotactic radiotherapy for prostate cancer: treatment approaches and clinical outcomes. (ver web)
The essential role of radiotherapy in the treatment of Merkel cell carcinoma: a study from the rare cancer network. Int. (ver web)
(coautor junto a Ghadjar P, Kaanders JH, Poortmans P, Zaucha R, Krengli M, Lagrange JL, Özsoy O, Nguyen TD, Baize A, Boujelbene N, Collen T, Scandolaro L, Untereiner M, Goldberg H, Pesce GA, Anacak Y, Friedrich EE, Aebersold DM, Beer KT). J. Radiat Oncol Biol Phys. 2011 Nov 15;81(4):e583-9.Breathing adapted radiotherapy: a 4D gating software for lung cancer. (ver web)
(coautor junto a Peguret N, Vock J, Vinh-Hung V, Fenoglietto P, Azria D, Zaidi H, Wissmeyer M, Ratib O). Radiat Oncol 2011 Jun 24;6:78.Outcome and risk factors for late-onset complications 24 months beyond allogeneic hematopoietic stem cell transplantation. (ver web)
(coautor junto a Bieri S, Roosnek E, Ozsahin H, Huguet S, Ansari M, Trombetti A, Helg C, Chapuis B, Passweg J, Chalandon Y).Eur J Haematol. 2011 Aug;87(2):138-47.Low-dose radiotherapy in indolent lymphoma. (ver web)
(coautor junto a Rossier C, Schick U, Mirimanoff RO, Weber DC, Ozsahin M).Int J Radiat Oncol Biol Phys. 2011 Nov 1;81(3):e1-6.High-dose brachytherapy boost to the dominant intra-prostatic tumor region: hemi-irradiation of prostate . (ver web)
(coautor junto a Schick U, Popowski Y, Nouet P, Bieri S, Rouzaud M, Khan H, Weber DC).Prostate. 2011 Sep;71(12):1309-16.Twice-weekly hypofractionated intensity-modulated radiotherapy for localized prostate cancer with low-risk nodal involvement: toxicity and outcome from a dose escalation pilot study. (ver web)
(coautores junto a Zilli T, Rouzaud M, Dipasquale G, Mollà M, Nouet P, Casanova N, Wang H, Weber DC).Int J Radiat Oncol Biol Phys. 2011 Oct 1;81(2):382-9.